Charlotte E. Coles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charlotte E. Coles has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Anna M. Kirby
Royal Marsden NHS Foundation Trust, Sutton, UK
3 shared publications Joanne S Haviland
Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK
3 shared publicationsJudith M Bliss
Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK
3 shared publicationsAnna M Kirby
Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK
2 shared publications- Cliona Clare Kirwan
Institute of Cancer Sciences, University of Manchester, University Hospital of South Manchester, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Oxford Road, Manchester M13 9PL, United Kingdom
2 shared publications - Joanne Haviland
Pragmatic Clinical Trials Unit, Centre for Evaluation and Methods, Faculty of Medicine and Dentistry, Wolfson Institute of Population Health Queen Mary University of London London UK
2 shared publications
Latest Publications
- 5 March 2026
- Published by Elsevier in The Lancet
- Vol. 407 (10532) , 920-921
Hypofractionated nodal radiotherapy in breast cancer: time for an updated standard of care?
- 5 March 2026
- Published by Elsevier in The Lancet
- Vol. 407 (10532) , 920-921
Hypofractionated nodal radiotherapy in breast cancer: time for an updated standard of care?
- Open Access
- 27 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111301
Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials
- 27 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111301
Open AccessBaseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials
- Open Access
- 23 July 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 211, 111056
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial
- 23 July 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 211, 111056
Open AccessFive-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial
- Open Access
- 21 January 2025
- Published by Elsevier in The Breast
- Vol. 80, 103881
The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy
- 21 January 2025
- Published by Elsevier in The Breast
- Vol. 80, 103881
Open AccessThe 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy
- 2 May 2024
- Published by Elsevier in The Lancet
- Vol. 403 (10438) , 1752
Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial – Authors' reply
- 2 May 2024
- Published by Elsevier in The Lancet
- Vol. 403 (10438) , 1752
Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial – Authors' reply
- 15 April 2024
- Published by Elsevier in The Lancet
- Vol. 403 (10439) , 1895-1950
The Lancet Breast Cancer Commission
- 15 April 2024
- Published by Elsevier in The Lancet
- Vol. 403 (10439) , 1895-1950
The Lancet Breast Cancer Commission
- Top Cited PapersOpen Access
- 8 June 2023
- Published by Elsevier in The Lancet
- Vol. 401 (10394) , 2124-2137
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
- 8 June 2023
- Published by Elsevier in The Lancet
- Vol. 401 (10394) , 2124-2137
Top Cited PapersOpen AccessDose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
- Open Access
- 17 November 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 197 (2) , 405-416
Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis
Purpose: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in either 15 (WB15F, PB15F) or 5 fractions (WB5F, PB5F). In a subgroup ineligible for PB radiotherapy, we compared WB15F to WB5F. Methods: We developed a Markov cohort model to simulate lifetime healthcare costs and quality-adjusted life years (QALYs) for each modality. This was informed by the clinical analysis of two non-inferiority trials (FAST Forward and IMPORT LOW) and supplemented with external literature. The primary analysis assumed that radiotherapy modality influences health only through its impact on locoregional recurrence and radiotherapy-related adverse events. Results: In the primary analysis, PB5F had the least cost and greatest expected QALYs. WB5F had the least cost and the greatest expected QALYs in those only eligible for WB radiotherapy. Applying a cost-effectiveness threshold of £15,000/QALY, there was a 62% chance that PB5F was the cost-effective alternative in the PB eligible group, and there was a 100% chance that WB5F was cost-effective in the subgroup ineligible for PB radiotherapy. Conclusions: Hypofractionation to 5 fractions and partial breast radiotherapy modalities offer potentially important benefits to the UK health system.
- 17 November 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 197 (2) , 405-416
Open AccessCost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis
Purpose: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in either 15 (WB15F, PB15F) or 5 fractions (WB5F, PB5F). In a subgroup ineligible for PB radiotherapy, we compared WB15F to WB5F. Methods: We developed a Markov cohort model to simulate lifetime healthcare costs and quality-adjusted life years (QALYs) for each modality. This was informed by the clinical analysis of two non-inferiority trials (FAST Forward and IMPORT LOW) and supplemented with external literature. The primary analysis assumed that radiotherapy modality influences health only through its impact on locoregional recurrence and radiotherapy-related adverse events. Results: In the primary analysis, PB5F had the least cost and greatest expected QALYs. WB5F had the least cost and the greatest expected QALYs in those only eligible for WB radiotherapy. Applying a cost-effectiveness threshold of £15,000/QALY, there was a 62% chance that PB5F was the cost-effective alternative in the PB eligible group, and there was a 100% chance that WB5F was cost-effective in the subgroup ineligible for PB radiotherapy. Conclusions: Hypofractionation to 5 fractions and partial breast radiotherapy modalities offer potentially important benefits to the UK health system.